GENENTECH, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1976-01-01

Employees: 11.1K

Market Cap: -

Website: http://www.gene.com

Clinical Trials

A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: bortezomib
Drug: SGN-40

First Posted Date: 2008-04-23

Last Posted Date: 2022-12-12

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 18

Registration Number: NCT00664898

Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Phase 3

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: pirfenidone

First Posted Date: 2008-04-21

Last Posted Date: 2017-03-29

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 1058

Registration Number: NCT00662038

Locations: 🇺🇸
Genentech, Inc., South San Francisco, California, United States

A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Vismodegib 150 mg
Drug: Placebo to vismodegib
Drug: Bevacizumab
Drug: Modified FOLFOX
Drug: FOLFIRI

First Posted Date: 2008-03-14

Last Posted Date: 2017-06-08

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 199

Registration Number: NCT00636610

A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)

Phase 3

Terminated

Conditions: Systemic Lupus Erythematosus
Lupus Nephritis

Interventions: Drug: Corticosteroids
Drug: Cyclophosphamide
Drug: Mycophenolate Mofetil
Drug: Placebo
Drug: Ocrelizumab
Drug: Azathioprine

First Posted Date: 2008-02-29

Last Posted Date: 2020-12-22

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 381

Registration Number: NCT00626197

GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: GDC-0449

First Posted Date: 2008-02-06

Last Posted Date: 2015-10-08

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 68

Registration Number: NCT00607724

A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer

Phase 3

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Placebo
Drug: Pertuzumab
Drug: Trastuzumab
Drug: Docetaxel

First Posted Date: 2007-12-04

Last Posted Date: 2019-12-13

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 808

Registration Number: NCT00567190

Locations: 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸
LAC USC Medical Center, Los Angeles, California, United States
🇺🇸
St. Barnabas Cancer Center, Livingston, New Jersey, United States

and more 312 locations

A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: rituximab
Drug: SGN-40

First Posted Date: 2007-11-12

Last Posted Date: 2014-03-20

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 22

Registration Number: NCT00556699

A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer

Phase 3

Completed

Conditions: Adenocarcinoma

Interventions: Drug: Capecitabine
Drug: Bevacizumab
Drug: Cisplatin
Drug: Placebo
Drug: 5-fluorouracil

First Posted Date: 2007-10-24

Last Posted Date: 2017-06-14

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 774

Registration Number: NCT00548548

Locations: 🇺🇸
Cancer Center of Kansas, Wichita, Kansas, United States
🇺🇸
Georgetown University, Washington, D.C., District of Columbia, United States
🇺🇸
USC/Norris Cancer Center, Los Angeles, California, United States

and more 10 locations

A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)

Phase 2

Terminated

Conditions: Chondrosarcoma

Interventions: Drug: PRO95780

First Posted Date: 2007-10-15

Last Posted Date: 2022-12-13

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 15

Registration Number: NCT00543712

Locations: 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Australia
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

A Study of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus

Phase 1

Completed

Conditions: Systemic Lupus Erythematosus

First Posted Date: 2007-10-10

Last Posted Date: 2011-09-22

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 60

Registration Number: NCT00541749

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy